Teva tightens Swiss franc tranche guidance on strong demand
Teva Pharmaceutical Industries, the Israeli generic drug company, revised guidance on its debut Swiss franc bond on Monday to 80bp over mid-swaps, from mid-swaps plus 85bp. The 6.5 year deal, maturing in 2018, is expected to be minimum Sfr250m ($221.46m) but already has an order book in excess of Sfr400m after opening on Monday morning. Pricing is expected this afternoon.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts